OverviewSuggest Edit

Synthorx is a biotechnology company using synthetic biology starting with its novel DNA base pair to discover and develop new protein therapeutics. The company uses new building blocks to create proteins that impart specificity not possible with native proteins. 

TypePublic
Founded2014
HQSan Diego, US
Websitesynthorx.com

Latest Updates

Employees (est.) (Mar 2019)39(+40%)
Share Price (Oct 2019)$12.3

Key People/Management at Synthorx

Laura Shawver

Laura Shawver

President, CEO, & Director
Marcos Milla

Marcos Milla

Chief Scientific Officer
Joseph Leveque

Joseph Leveque

Chief Medical Officer
Tighe Reardon

Tighe Reardon

Acting Chief Financial Officer
Christian V. Kuhlen

Christian V. Kuhlen

General Counsel
Floyd Romesberg

Floyd Romesberg

Scientific Founder and Director
Show more

Synthorx Office Locations

Synthorx has an office in San Diego
San Diego, US (HQ)
11099 N Torrey Pines Rd #290, La Jolla
Show all (1)

Synthorx Financials and Metrics

Synthorx Revenue

USD

Net income (FY, 2017)

(5.8m)

EBIT (FY, 2017)

(5.8m)

Market capitalization (16-Oct-2019)

395.6m

Closing stock price (16-Oct-2019)

12.3

Cash (30-Sep-2018)

57.8m
Synthorx's current market capitalization is $395.6 m.
USDFY, 2016FY, 2017

General and administrative expense

1.2m1.9m

R&D expense

1.9m3.9m

Operating expense total

3.1m5.9m

EBIT

(3.1m)(5.8m)
Annual
USDFY, 2016FY, 2017

Cash

4.1m3.7m

Prepaid Expenses

15.0k66.0k

Current Assets

4.1m3.7m

PP&E

431.0k692.0k
Quarterly
USDQ3, 2018

Cash

57.8m

Prepaid Expenses

135.0k

Current Assets

57.9m

PP&E

1.3m
Annual
USDFY, 2016FY, 2017

Net Income

(3.1m)(5.8m)

Depreciation and Amortization

32.0k114.0k

Cash From Operating Activities

(2.8m)(5.1m)

Purchases of PP&E

(403.0k)(388.0k)
Quarterly
USDQ3, 2017Q3, 2018

Net Income

(3.7m)(28.4m)

Depreciation and Amortization

76.0k162.0k

Cash From Operating Activities

(3.1m)(9.3m)

Purchases of PP&E

(219.0k)(712.0k)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Synthorx Online and Social Media Presence

Embed Graph

Synthorx News and Updates

Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707

In addition, the company has received clearance from the Food and Drug Administration (FDA) for the Investigational New Drug (IND) Application for THOR-707, paving the way for patient enrollment to proceed in the U.S. The single agent and combination arms of the trial are evaluating the safety, tole…

Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN DIEGO, May 15, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company discovering and developing optimized biologics for cancer and autoimmune disorders, today announced company researchers will present preclinical data demonstrating the potential safety and anti-tumor…

Synthorx Reports Fourth Quarter and Full Year 2018 Financial Results

Company Positioned for Upcoming 2019 Milestones After Successful IPO Raising $150.7 Million in Gross Proceeds

Synthorx Announces Pricing of Initial Public Offering

SAN DIEGO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the pricing of its initial pu…

Synthorx to Present Preclinical Data for THOR-707, a "Not-Alpha" IL-2 Synthorin, for the Treatment of Solid Tumors at SITC 2018

SAN DIEGO, Nov. 9, 2018 /PRNewswire/ -- Synthorx, Inc., a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced company researchers will present results ...

Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer

SAN DIEGO, Aug. 16, 2018 /PRNewswire/ -- Synthorx, Inc., a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform to discover and develop innovative protein therapeutics for cancer, autoimmune disorders and other serious diseases, today announced the...

Synthorx Frequently Asked Questions

  • When was Synthorx founded?

    Synthorx was founded in 2014.

  • Who are Synthorx key executives?

    Synthorx's key executives are Laura Shawver, Marcos Milla and Joseph Leveque.

  • How many employees does Synthorx have?

    Synthorx has 39 employees.

  • Who are Synthorx competitors?

    Competitors of Synthorx include Urovant Sciences, Verrica Pharmaceuticals and SciBac.

  • Where is Synthorx headquarters?

    Synthorx headquarters is located at 11099 N Torrey Pines Rd #290, La Jolla, San Diego.

  • Where are Synthorx offices?

    Synthorx has an office in San Diego.

  • How many offices does Synthorx have?

    Synthorx has 1 office.